Description: XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Vancouver, Canada.
Home Page: www.xortx.com
XRTX Technical Analysis
421 – 7th Avenue SW
Vancouver,
BC
T2P 4K9
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Dr. Allen Warren Davidoff Ph.D. | Founder, CEO, Pres & Director |
| Mr. Amar Keshri C.A., CPA | Chief Financial Officer |
| Nick Rigopoulos | Director of Communications |
| Dr. David Sans M.B.A., Ph.D. | Director of Corp. Devel. |
| Dr. Stephen Haworth M.D., MRCP | Chief Medical Officer |
| Dr. David MacDonald Ph.D. | Consultant of Clinical Operations |
| Dr. Stacy Evans M.B.A., M.D. | Chief Bus. Officer |
| Ms. Charlotte May | Corp. Sec. |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0.9658 |
|---|---|
| Trailing PE: | 1.9615 |
| Price-to-Book MRQ: | 1.5456 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |